Democrats will hold a 56-44 Senate majority beginning in January
The U.S. Senate will not confirm anyone to lead the Food and Drug Administration until Democrats take control of the chamber in January, according to News From The States. Louisiana Republican Sen. Bill Cassidy, chairman of the panel that oversees FDA nominations, said Tuesday night that he did not intend to rush anyone through during the lame-duck session, which lasts through mid-December.
The decision came shortly after the White House withdrew Dr. Heidi Overton, who had been scheduled for a Wednesday vote in the Health, Education, Labor and Pensions Committee. Overton testified before the panel in September as part of the confirmation process.
Cassidy challenged the White House’s explanation for withdrawing Overton. “Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” he wrote in a social media post. He said the administration attributed the withdrawal to Overton’s lack of votes, but that he was having productive conversations with members and believed she had enough votes to pass both the committee and the full Senate.
Cassidy said his conversations with Overton convinced him she would follow the science and push back against decisions that put Americans’ health at risk. He said pro-life senators sought final assurances from the administration regarding its commitment to life issues, and that the White House withdrew Overton’s nomination rather than make those commitments. “Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats,” Cassidy wrote.
Missouri Republican Sen. Josh Hawley said in a brief Tuesday hallway interview, before the White House withdrew Overton’s nomination, that he was encouraged by her answers to questions he sent after the hearing. Hawley said he had sent a couple of pages of new questions a few weeks earlier and liked the responses she provided.
Hawley said Overton committed to finish the FDA’s mifepristone study by March of 2027, use the most recent data, and use private commercial data, including insurer data, when necessary to provide a complete picture. Hawley was among several senators who pressed Overton during her confirmation hearing about her beliefs concerning medication abortion.
Hawley said he did not know whether the committee would still vote on advancing Overton’s nomination several hours before that part of the markup was canceled. “I know that there’s building frustration on the committee about the inability of the committee to figure out what it’s doing,” he said. “My colleagues are getting a little irritated.”
Overton’s hearing focused in part on medication abortion. The two-drug regimen consisting of mifepristone and misoprostol is FDA-approved for up to 10 weeks gestation. It can be prescribed through telehealth and shipped by mail, a change the FDA made during the Biden administration that many Republicans want reversed.
The FDA has conducted its own safety review for much of the last two years. Former Commissioner Marty Makary was forced out in May amid frustration from anti-abortion groups because the agency did not plan to release its report before the midterm elections.
Susan B. Anthony Pro-Life America had encouraged the committee to delay a confirmation vote for Overton. In a statement released Nov. 11, Senior Vice President of Legal Strategy Erik Baptist wrote that “senators must secure commitments from the administration that it will immediately restore the in-person dispensing requirement for mifepristone and address the serious flaws with the FDA’s mifepristone safety study.”
Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, and Lila Rose, founder of Live Action, also released statements in December pressing for the FDA to restrict access to mifepristone. Dannenfelser wrote that the FDA needed a new commissioner who would immediately restore in-person dispensing as it existed under President Trump’s first term and conduct a comprehensive study. She also said: “Commissioner Makary is severely undermining President Trump and Vice President Vance’s pro-life credentials and their position that states should have the right to enact and enforce pro-life protections. Makary must go.”
Democrats flipped nine Senate seats in this month’s midterm elections and will hold a 56-44 majority starting in January. The White House did not immediately respond to a request for comment, leaving the Food and Drug Administration without a confirmed permanent commissioner while the agency continues its safety review and Congress changes hands.